Inducing Oncoprotein Degradation to Improve Targeted Cancer Therapy
Over the past decade, inhibition of the kinase activities of oncogenic proteins using small molecules and antibodies has been a mainstay of our anticancer drug development effort, resulting in several Food and Drug Administration–approved cancer therapies. The clinical effectiveness of kinase-target...
Main Authors: | Dipankar Ray, Kyle C. Cuneo, Alnawaz Rehemtulla, Theodore S. Lawrence, Mukesh K. Nyati |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2015-09-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558615001049 |
Similar Items
-
Overcoming Intratumor Heterogeneity of Polygenic Cancer Drug Resistance with Improved Biomarker Integration
by: Alnawaz Rehemtulla
Published: (2012-12-01) -
TGFBR2 mediated phosphorylation of BUB1 at Ser-318 is required for transforming growth factor-β signaling
by: Shyam Nyati, et al.
Published: (2020-04-01) -
The War on Cancer Rages On
by: Alnawaz Rehemtulla
Published: (2009-12-01) -
The Interconnectedness of Cancer Cell Signaling
by: Alnawaz Rehemtulla
Published: (2011-12-01) -
Efficacy of an EGFR-Specific Peptide against EGFR-Dependent Cancer Cell Lines and Tumor Xenografts
by: Aarif Ahsan, et al.
Published: (2014-02-01)